09.08.26 -- Preserving Tacit Knowledge In ADC Tech Transfers

An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

Dive into the scope of <382> for pharmaceutical closures and the regulatory landscape, which includes new required tests, instrumentation for compliance, and recommendations on implementation.

Biotech visibility improves through real-time data and centralized platforms, enabling collaboration, faster decisions, reduced risk, and better partner alignment.

For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.

Animal‑free raw materials ensure reliable bioprocessing through stable molecular weight profiles, consistent mineral levels, and controlled manufacturing for dependable lot‑to‑lot performance.

Aligning early upstream choices, downstream purification, and analytical testing prevents scale-up delays, reduces process variability, and protects timelines for complex biologics.

Maider Parikh, VP of Commercial Operations, reveals how top biopharma teams are tackling timeline pressure, regulatory complexity, and supply chain risk. Access the full Q&A to benchmark your approach.

Bispecific antibody release testing is more complex than standard mAbs. Learn which analytical methods matter most, from CE-SDS and cIEF to DAR testing for ADCs, and why each earns its place in the panel.

A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety.